Manufacturing Deficiencies Behind FDA's Oxylanthanum Carbonate Rejection

Oxylanthanum carbonate, an investigational phosphate binder developed by Unicycive Therapeutics for hyperphosphatemia in patients with chronic kidney disease on dialysis, has received a second Complete Response Letter (CRL) from the FDA.1 The agency raised no concerns about clinical efficacy or safety and requested no additional data. Instead, the rejection rests entirely on unresolved compliance deficiencies at the third-party manufacturing vendor responsible for producing the drug substance, the same deficiencies cited in the original CRL issued in June 2025.

Between the two decisions, the company had pursued a now-familiar regulatory sequence: a Type A meeting with the agency in September 2025, an EU inspection of the same vendor that found no deficiencies, and a resubmission of the New Drug Application built on the vendor's reported progress toward inspection readiness.1,2 Despite that progress, the FDA had not completed its own inspection of the facility by the time of the second decision, leaving the compliance question unresolved and the application unapprovable on chemistry, manufacturing, and controls grounds alone.

What Types of Deficiencies Trigger CRL for a Third-Party Manufacturer?

CRLs tied solely to chemistry, manufacturing, and controls (CMC issues generally stem from facility-level compliance findings rather than problems with the drug product itself.1 Common triggers include unresolved findings from a pre-approval inspection, data integrity concerns, deviations from current good manufacturing practice, or failure to demonstrate inspection readiness within the review cycle. In this case, the company has stated that the citations at the vendor were not specific to oxylanthanum carbonate production, underscoring a recurring theme in CMC rejections: a facility's broader compliance status can stall an otherwise clean application, independent of how the investigational product itself performs. This distinction shifts the resolution pathway away from additional clinical work and toward facility remediation, an inspection, and confirmation of compliance, none of which the sponsor directly controls.

How Should Sponsors Avoid Resubmission Delays?

The case illustrates the value and the limits of contingency planning around contract manufacturing.1 The company identified and qualified a second manufacturing vendor that had already produced drug product following the first rejection, yet the resubmission still relied on the original vendor's compliance status, and the second rejection again hinged on that same facility. The lesson for sponsors managing third-party manufacturing relationships is that qualifying a backup vendor is necessary but not sufficient; the qualification timeline, validation batches, and any required inspections need to run far enough ahead of a Prescription Drug User Fee Act target date that switching vendors does not itself become the source of delay. Sponsors that wait until a CRL arrives to activate a secondary supply path risk repeating the same compliance dependency that triggered the original rejection, since regulatory timelines for vendor transitions rarely compress to match a resubmission cycle already in progress.

What Does This Mean for Novel Oral Solid Dosage Forms?

Oxylanthanum carbonate is formulated using proprietary nanoparticle technology intended to increase phosphate-binding potency and reduce pill burden compared with existing binders, a formulation approach gaining traction across oral solid dosage development as sponsors seek to improve adherence in chronic disease populations.1,2 This case is a reminder that novel particle-engineering platforms often depend on specialized contract manufacturers with the equipment and process expertise to produce them at scale, narrowing the pool of qualified vendors and concentrating regulatory risk at the facility level. As more oral solid dosage candidates rely on nanoparticle-based drug delivery, sponsors and their manufacturing partners should expect facility compliance history and inspection readiness to weigh as heavily on approval timelines as the underlying formulation science, particularly when specialized production capacity is limited and difficult to replicate quickly across alternate sites.

References

1. Reuters. US FDA declines to approve Unicycive’s drug for dialysis patients. Press Release. June 30, 2026. https://www.reuters.com/legal/litigation/us-fda-declines-approve-unicycives-drug-dialysis-patients-2026-06-30/
2. Unicycive Therapeutics, Inc. Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA). Press Release. June 30, 2026. https://ir.unicycive.com/news/detail/123/unicycive-therapeutics-receives-complete-response-letter